Literature DB >> 3520827

The adoptive immunotherapy of cancer using the transfer of activated lymphoid cells and interleukin-2.

S A Rosenberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3520827

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  10 in total

Review 1.  The interleukins in acquired disease.

Authors:  M Malkovský; P M Sondel; W Strober; A G Dalgleish
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

2.  Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas.

Authors:  K B Quattrocchi; C H Miller; S Cush; S A Bernard; S T Dull; M Smith; S Gudeman; M A Varia
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

3.  T-cell abnormality and defective interleukin-2 production in patients with carcinoma of the urinary bladder with schistosomiasis.

Authors:  S Raziuddin; S Shetty; A Ibrahim
Journal:  J Clin Immunol       Date:  1991-03       Impact factor: 8.317

4.  Successful adoptive immunotherapy of minimal residual disease after chemoradiotherapy and transplantation of bone marrow purged of leukaemia with mafosfamide.

Authors:  T Skórski; M Kawalec; J Kawiak
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

5.  Injection of recombinant tumor necrosis factor directly into liver metastases: an experimental and clinical approach.

Authors:  J N IJzermans; M Scheringa; G P van der Schelling; R A Geerling; R L Marquet; J Jeekel
Journal:  Clin Exp Metastasis       Date:  1992-03       Impact factor: 5.150

6.  Generation of lymphokine-activated killer cells does not require DNA synthesis.

Authors:  M Malkovský; M Jíra; J Madar; V Malkovska; B Loveland; G L Asherson
Journal:  Immunology       Date:  1987-03       Impact factor: 7.397

7.  Lymphokine-activated killer cell activity in rheumatoid arthritis.

Authors:  M Jíra; M Malkovský; A M Denman; B Loveland; D Lyons; A G Dalgleish; A D Webster
Journal:  Clin Exp Immunol       Date:  1987-06       Impact factor: 4.330

8.  Lysis of fresh murine mammary tumor cells by syngeneic natural killer cells and lymphokine-activated killer cells.

Authors:  I H Ames; C E Gates; A M Garcia; P A John; A K Hennig; R H Tomar
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

9.  Alloimmune cells consume interleukin-2 and competitively inhibit the anti-tumour effects of interleukin-2.

Authors:  A M Eggermont; E P Steller; W Matthews; P H Sugarbaker
Journal:  Br J Cancer       Date:  1987-08       Impact factor: 7.640

10.  Three schedules of recombinant human interleukin-2 in the treatment of malignancy: side effects and immunologic effects in relation to serum level.

Authors:  T Sano; N Saijo; Y Sasaki; T Shinkai; K Eguchi; T Tamura; M Sakurai; H Takahashi; H Nakano; K Nakagawa
Journal:  Jpn J Cancer Res       Date:  1988-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.